Antigen Express, Inc.
Records under this name other than patents Antigen Express, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,935,350 | Ii-key/Her-2/neu hybrid cancer vaccine Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,889,143 | Ii-key/HER-2/neu hybrid cancer vaccine Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,748,130 | Human papillomavirus / Ii-Key hybrids and methods of use Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,179,645 | II-Key/Antigenic Epitope Hybrid Peptide Vaccines Formerly held Term ended Term ended Nov 6, 2023 · High confidence | Term ended | Term ended Nov 6, 2023 | High confidence |
| US 9,289,487 | II-Key/Antigenic Epitope Hybrid Peptide Vaccines Formerly held Term ended Term ended May 19, 2023 · Medium confidence | Term ended | Term ended May 19, 2023 | Medium confidence |
| US 7,205,274 | Hybrid Peptides Modulate the Immune Response Term ended Term ended Nov 27, 2020 · Medium confidence | Term ended | Term ended Nov 27, 2020 | Medium confidence |
| US 6,432,409 | Hybrid peptides modulate the immune response Term ended Term ended Sep 14, 2019 · From the USPTO record | Term ended | Term ended Sep 14, 2019 | From the USPTO record |
| US 8,815,249 | II-Key/Antigenic Epitope Hybrid Peptide Vaccines Term ended Term ended Sep 14, 2019 · Medium confidence | Term ended | Term ended Sep 14, 2019 | Medium confidence |
| US 7,541,334 | Hybrid peptides modulate the immune response Lapsed on the fee record Ended Jun 2, 2017 · From the USPTO record | Lapsed on the fee record | Ended Jun 2, 2017 | From the USPTO record |
| US 6,368,855 | MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression Term ended Term ended Jun 11, 2016 · From the USPTO record | Term ended | Term ended Jun 11, 2016 | From the USPTO record |